Innovative Biotech Solutions

---

Dr. Mark Daniels is a Principal Consultant at Meridian Technology Advisors, where he provides strategic technology advisory services to organizations navigating complex digital, data, and infrastructure challenges. With over 30 years of experience spanning healthcare, research, defense, and commercial sectors, Mark brings a rare combination of deep technical expertise and executive leadership to the organizations he serves. He is a trusted advisor to leaders seeking to align business objectives with scalable architectures, modern platforms, and emerging technologies — including advanced analytics and AI.

Mark is recognized for his ability to grasp the big picture while managing the technical depth required to architect and deliver enterprise-scale solutions. His expertise spans clinical data systems, enterprise architecture, health information exchange, data warehousing, and health informatics. He is equally at home in the boardroom developing technology strategy and in the trenches solving complex integration and data challenges. For small biotech companies, this means access to a seasoned technologist who understands the rigors of research and clinical environments and can help build the data infrastructure needed to meet regulatory expectations and investor milestones.

Dr. Daniels holds a Doctor of Philosophy in Computer Science & Engineering from the University of South Carolina, a Master of Science in Computer Science from The Johns Hopkins University, and a Bachelor of Science in Computer Science from the College of Charleston. He is a Fellow of the Healthcare Information and Management Systems Society (HIMSS) and holds certifications in Project Management (PMP) and ITIL Foundations.

As Chief Technology Officer and Deputy CIO for Academics & Research at the Medical University of South Carolina (MUSC) — one of the nation's premier academic medical centers — Mark served for over three decades, culminating in his role as CTO from 2018 to 2026. In that capacity, he served as chief information technology strategist, developed enterprise technology roadmaps, and led large-scale architectural initiatives spanning clinical care, research, and academic operations.

Mark's landmark achievements at MUSC include leading the design and implementation of the institution's first Enterprise Data Warehouse, overseeing Epic EMR integration, establishing Health Information Exchange (HIE) connections, and directing the selection and negotiation of a new enterprise ERP system. He also served as Adjunct Associate Professor in MUSC's Master of Healthcare Informatics program for over a decade, teaching courses in Electronic Health Records, Advanced Health Information Technology, and Healthcare Data Standards.

Prior to MUSC, Mark served as a Systems Integrator and Software Engineer at The BDM Corporation, where he led software development and integration efforts on mission-critical programs for the Department of Defense, including systems for nuclear weapons effects modeling, data link vulnerability analysis, and intelligence systems for the US Marine Corps.

Dr. Daniels is a published researcher with contributions to peer-reviewed journals and conference proceedings in health data privacy, predictive analytics, and clinical informatics. Notable publications include work on health data privacy presented at IEEE and ACM international conferences, a dissertation on ontology-guided inference disruption, and a co-authored study on predictive analytics for kidney transplant outcomes published in the American Journal of Transplantation.

Mark's unique background bridges the worlds of clinical data, research informatics, and enterprise technology strategy. For small biotech companies, he offers the kind of seasoned perspective that is typically only available at large institutions — helping organizations build regulatory-ready data systems, navigate health data privacy requirements, leverage AI and analytics for research acceleration, and establish the technology infrastructure needed to support clinical trials and investor confidence.